Utilizing Protein Carriers to Engineer More Potent Cancer Vaccines
Despite the clinical success of several immunomodulatory agents in oncology, cancer vaccines have thus far disappointed in the clinic. A major reason for this could be the low bioavailability of peptide vaccines in lymphoid organs that orchestrate the immune response. By anchoring vaccine cargo to protein carriers, we enhance immunogenicity and improve anti-tumor responses in a therapeutic setting. Additionally, because both cargo and carrier are genetically encodable, this strategy may enable a diverse array of vaccination modalities.